ReShape Lifesciences Net Worth

ReShape Lifesciences Net Worth Analysis

ReShape Lifesciences Target Price Consensus

ReShape Lifesciences Target Price Projection

ReShape Lifesciences' current and average target prices are 2.32 and 1.00, respectively. The current price of ReShape Lifesciences is the price at which ReShape Lifesciences is currently trading. On the other hand, ReShape Lifesciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on ReShape Lifesciences and the information provided on this page.

Know ReShape Lifesciences' Top Institutional Investors

Note, although ReShape Lifesciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow ReShape Lifesciences' market capitalization trends

The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.68 M.

Project ReShape Lifesciences' profitablity

The company has Profit Margin (PM) of (0.48) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.65) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.65.

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Evaluate ReShape Lifesciences' management efficiency

ReShape Lifesciences has return on total asset (ROA) of (0.535) % which means that it has lost $0.535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2016) %, meaning that it created substantial loss on money invested by shareholders. ReShape Lifesciences' management efficiency ratios could be used to measure how well ReShape Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, ReShape Lifesciences' Return On Capital Employed is comparatively stable compared to the past year. Return On Equity is likely to gain to 29.59 in 2025, whereas Return On Tangible Assets are likely to drop (1.56) in 2025. At this time, ReShape Lifesciences' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 4 M in 2025, whereas Other Assets are likely to drop slightly above 111.4 K in 2025. ReShape Lifesciences time-series forecasting models is one of many ReShape Lifesciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ReShape Lifesciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

ReShape Lifesciences Earnings Estimation Breakdown

The calculation of ReShape Lifesciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of ReShape Lifesciences is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for ReShape Lifesciences is based on EPS before non-recurring items and includes expenses related to employee stock options.

ReShape Lifesciences Earnings Projection Consensus

ReShape Lifesciences Earnings per Share Projection vs Actual

Actual Earning per Share of ReShape Lifesciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering ReShape Lifesciences predict the company's earnings will be in the future. The higher the earnings per share of ReShape Lifesciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

ReShape Lifesciences Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as ReShape Lifesciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of ReShape Lifesciences should always be considered in relation to other companies to make a more educated investment decision.

ReShape Quarterly Analyst Estimates and Surprise Metrics

ReShape Lifesciences Corporate Management

Additional Tools for ReShape Stock Analysis